Orbital Therapeutics develops RNA-based medicines using a technology-agnostic platform that calibrates expression, duration, and tissue distribution to target specific disease biologies. This approach enhances the efficacy of RNA therapies, addressing the limitations of traditional treatments in precision medicine.
Funding
$301.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional treatments often fall short in precision medicine due to their limited ability to target specific disease biologies with tailored expression, duration, and tissue distribution. This can lead to suboptimal efficacy and increased side effects.
Solution
Orbital Therapeutics is developing RNA-based medicines using a technology-agnostic platform designed to overcome the limitations of existing therapies. Their approach calibrates expression levels, therapeutic duration, and tissue distribution to precisely target specific disease mechanisms. By aligning drug design with the underlying biology of the disease, Orbital aims to enhance the efficacy and safety of RNA medicines, expanding their reach and impact on human health. The company leverages a comprehensive suite of state-of-the-art technologies to engineer RNA medicines tailored to specific disease biologies.
Target Audience
The primary target audience includes patients with diseases that are not adequately addressed by existing treatments, as well as healthcare providers seeking more precise and effective therapeutic options.
Features
- Technology-agnostic platform for designing RNA medicines
- Precise control over expression levels, duration, and tissue distribution
- Targeted approach to address specific disease biologies
- Enhanced efficacy and safety profiles compared to traditional treatments
- Comprehensive range of state-of-the-art technologies